Please use this identifier to cite or link to this item: https://www.um.edu.mt/library/oar/handle/123456789/55101
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMicallef, Mark J.-
dc.contributor.authorDarmanin, Stephanie-
dc.contributor.authorBuhagiar, Joseph A.-
dc.contributor.authorCamilleri-Podesta, Marie Therese-
dc.contributor.authorYamauchi, Hiroshi-
dc.contributor.authorKurimoto, Masashi-
dc.contributor.authorSerracino-Inglott, Anthony-
dc.contributor.authorEllul-Micallef, Roger-
dc.date.accessioned2020-04-29T12:02:25Z-
dc.date.available2020-04-29T12:02:25Z-
dc.date.issued2001-
dc.identifier.citationMicallef, M. J., Darmanin, S., Buhagiar, J. A., Camilleri-Podesta, M. T., Yamauchi, H., Kurimoto, M., ... & Ellul-Micallef, R. (2001). Interferon gamma induction in human melanoma cell/allogeneic leukocyte co-cultures is enhanced by interleukin 18 but drug resistant melanoma cells are poorer inducers of IFN-γ. International Immunopharmacology, 1(2), 295-305.en_GB
dc.identifier.urihttps://www.um.edu.mt/library/oar/handle/123456789/55101-
dc.description.abstractHuman melanoma Colo 679 cells were made resistant to doxorubicin (adriamycin, ADM) by continuous exposure to ascending concentrations of the drug and Colo/ADM80; a variant which grew continuously in the presence of 80 ng/ml of ADM was thus established. Human peripheral blood mononuclear cells (PBMC) produced interferon gamma (IFN-gamma) when cultured with mitomycin C (MMC)-treated parental Colo 679 cells. The synthesis of IFN-gamma was synergistically enhanced by adding interleukin-18 (IL-18) and this was IL-12-dependent because a neutralizing antibody against IL-12 almost completely inhibited IFN-gamma production while control antibodies (Abs) were inactive. The cellular sources of IFN-gamma were found to be B cells, CD8+ T cells and CD4+ T cells as revealed by flow cytometry after double staining for surface antigens and staining for intracellular IFN-gamma. Interestingly, the resistant cell line induced much less IFN-gamma production than the parental cell line under the same co-culture conditions; however, IL-18 could still enhance the production of IFN-gamma. In conclusion, our study shows that acquired resistance to anti-cancer agents can also reduce immune responses to cancer cells. However, the immunostimulatory cytokine IL-18 could still enhance IFN-gamma production in drug resistant tumor cell-PBMC cultures indicating that such immunostimulatory agents could still be beneficial in immunotherapy for patients with recurrent drug resistant tumors.en_GB
dc.language.isoenen_GB
dc.publisherElsevieren_GB
dc.rightsinfo:eu-repo/semantics/restrictedAccessen_GB
dc.subjectMelanoma -- Pathophysiologyen_GB
dc.subjectMelanoma -- Diagnosisen_GB
dc.subjectMelanoma -- Treatmenten_GB
dc.subjectCell interactionen_GB
dc.subjectDrug resistance in cancer cellsen_GB
dc.subjectImmunosuppressionen_GB
dc.subjectDoxorubicinen_GB
dc.titleInterferon gamma induction in human melanoma cell/allogeneic leukocyte co-cultures is enhanced by interleukin 18 but drug resistant melanoma cells are poorer inducers of IFN-gammaen_GB
dc.typearticleen_GB
dc.rights.holderThe copyright of this work belongs to the author(s)/publisher. The rights of this work are as defined by the appropriate Copyright Legislation or as modified by any successive legislation. Users may access this work and can make use of the information contained in accordance with the Copyright Legislation provided that the author must be properly acknowledged. Further distribution or reproduction in any format is prohibited without the prior permission of the copyright holder.en_GB
dc.description.reviewedpeer-revieweden_GB
dc.identifier.doi10.1016/s1567-5769(00)00026-6-
dc.publication.titleInternational Immunopharmacologyen_GB
Appears in Collections:Scholarly Works - FacM&SPha

Files in This Item:
File Description SizeFormat 
Interferon_gamma_induction_in_human_melanoma.pdf
  Restricted Access
510.56 kBAdobe PDFView/Open Request a copy


Items in OAR@UM are protected by copyright, with all rights reserved, unless otherwise indicated.